2016 ESMO General View

C. Langer discusses Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G during Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

Copenhagen, - ESMO 2016 - C. Langer discusses Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G during Presidential Symposium 2: at the European Society of Medical Oncology's Asia (ESMO) meeting at the Bella Center here today, Sunday October 9, 2016. The new meeting is the premier oncology event in Europe for basic, translational, clinical and population science. Photo by © MedMeetingImages/Todd Buchanan 2016

16ESMO02695C. Langer discusses Randomizedphase 2 study of carboplatin and pemetrexed with or without pembrolizumab as firstline therapy for advanced NSCLC KEYNOTE021 cohort G during Randomizedphase 2 study of carboplatin and pemetrexed with or without pembrolizumab as firstline therapy for advanced NSCLC KEYNOTE021 cohort G ESMO 2016